Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3

5 Aug 2015

Abstract excerpt

BACKGROUND: Doses of the GH receptor (GHR) antagonist pegvisomant (PEGV) that normalize insulin-like growth factor 1 (IGF1) levels vary widely among acromegaly patients. Predictors for PEGV response are baseline IGF1 levels, sex, body weight and previous radiotherapy. A GHR polymorphism lacking exon 3 (d3-GHR) is frequent in the general population. The influence of d3-GHR on PEGV responsiveness in acromegaly is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycogen Storage Diseases and Myoclonus
Share to Growth Hormone and Insulin-like Growth Factors
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26243033
DOI: 10.1530/eje-15-0519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3PMID 26243033Read ↗

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.Semantic proximity Read ↗

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.Semantic proximity Read ↗

The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.Semantic proximity Read ↗

The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.Semantic proximity Read ↗

Treatment of acromegaly in the era of personalized and predictive medicine.Semantic proximity Read ↗

Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.Semantic proximity Read ↗

Genetic Predictors of Response to Different Medical Therapies in Acromegaly.Semantic proximity Read ↗

Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience.Semantic proximity Read ↗

Management of endocrine disease: GH excess: diagnosis and medical therapy.Semantic proximity Read ↗

Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with AcromegalySemantic proximity Read ↗

d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.Semantic proximity Read ↗

Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral PhenotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.